- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07867496
Exploration of Tolerability and Dose Responses for a Yeast-based Probiotic
The purpose of this study is to evaluate the tolerability and efficacy of a yeast-based dietary supplement on gastrointestinal, mental, and skin health. Yeasts are naturally present on fruits and plants, and are used to bake bread, beer and wine. Some of these yeasts are commonly consumed and may actually benefit your gut health. The supplemental yeast could strengthen the gut lining or help good bacteria in the gut grow better.
In this study, the investigators will look at how two doses of a yeast-based supplement impacts gut health, bowel movement consistency, and mental health. The study will last 17 weeks and consist of 7 clinic visits (1 screening visit and 6 test visits).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This study will take place at Colorado State University in Fort Collins, Colorado, USA. It will last approximately 17 weeks. This is a randomized, double-blind 3-arm crossover study with three treatments (placebo and two doses of Pichia kluyveri). The treatments will be taken for 4 weeks in a random order by every participant. Each treatment phase is separated by a 2-week washout. The first visit is a screening visit, where investigators will determine eligibility. Visit 2-7 are test visits where investigators will collect information on height, weight, waist, and hip measurements. Blood pressure will also be measured and the visit will conclude with a venous blood draw. During this visit, participants will also complete questionnaires about gut, mental, and skin health, menopause symptoms, and physical activity. A stool sample and bowel movement and diet records will be completed at home.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Jenny Whittington, MS
- Telefonnummer: 970-310-6843
- E-post: ijwhitt@rams.colostate.edu
Studer Kontakt Backup
- Navn: Tiffany L Weir, PhD
- Telefonnummer: 970-215-7571
- E-post: tiffany.weir@colostate.edu
Studiesteder
-
-
Colorado
-
Fort Collins, Colorado, Forente stater, 80521
- Colorado State University
-
Hovedetterforsker:
- Tiffany Weir, PhD
-
Ta kontakt med:
- Tiffany Weir, PhD
- Telefonnummer: 970-215-7571
- E-post: tiffany.weir@colostate.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- between 18-75 years old
- BMI <30 kg/m2
- mild/moderate gastrointestinal distress
Exclusion Criteria:
- Have taken antibiotics within two months of enrollment in the study
- Are currently taking statins, metformin, NSAIDs, and MAO inhibitors or other medications that could interfere with study outcomes, as determined by the study PI
- Have a current diagnosis of cancer, liver or kidney disease, gastrointestinal diseases (including Celiac, Crohn's, Ulcerative Colitis), and cardiometabolic disorders (cardiovascular disease, diabetes, etc.)
- Are pregnant or breastfeeding, or actively trying to lose weight
- Use excessive alcohol
- Use of supplements containing probiotics at any dose or if you are participating in other studies that may interfere with the bacteria in your gut.
- Unable or unwilling to consume capsules, provide stool or blood samples, track bowel movements and symptoms, and attend scheduled clinic visits.
- Have allergies to study treatments or medical supplies (eg. Latex, yeast, cellulose)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Placebo - cellulose and hypromellose |
|
Eksperimentell: Pichia kluyveri 9.9 x 10^7
|
9.9 x 10^7 Pichia kluyveri in microcrystalline cellulose and hypromellose |
|
Eksperimentell: Pichia kluyveri 1 x 10^8
|
1 x 10^8 Pichia kluyveri in microcrystalline cellulose and hypromellose |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Severity of gastrointestinal symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)
Tidsramme: 4 weeks
|
The Gastrointestinal Symptom Rating Scale (GSRS) is a widely used tool for measuring gastrointestinal symptoms across five domains. The GSRS is scored between "No discomfort" and "Very severe discomfort" |
4 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Systemic inflammation indicated by circulating Tumor Necrosis Factor Alpha
Tidsramme: 4 weeks
|
Tumor necrosis factor alpha, or TNF-a, is an inflammatory cytokine that is implicated in many diseases. |
4 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- 8533
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .